{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:03:00Z","timestamp":1784300580561,"version":"3.55.0"},"reference-count":18,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Radiopharmaceutical therapy, a form of targeted radionuclide therapy, has emerged as a rapidly advancing area in prostate cancer management, with significant developments in 2025. The field, which began to transform from pain palliation to cancer\u2010directed end points with the \u03b1\u2010emitting agent radium\u2010223 for bone\u2010predominant metastatic androgen pathway modulator resistant (mAPMR) disease, expanded considerably following the introduction of prostate\u2010specific membrane antigen targeted imaging and therapy. The approval of\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010PSMA\u2010617 in 2022 opened the door to exploring its benefit across the disease continuum and in combination with contemporary systemic and local treatments, with the goal of improving survival while maintaining safety. The year 2025 produced some of the most impactful advances to date. In the mAPMR setting, regulatory approval of\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010PSMA\u2010617 was extended into the pre\u2010chemotherapy state based on the PSMAfore trial. Also, in mAPMR disease, the PEACE\u20103 trial established the combination of radium\u2010223 with enzalutamide as an option when bone protective agents are used. Beyond the resistant setting, radiopharmaceuticals are being evaluated as treatment\u2010intensification strategies earlier in the disease course. In the metastatic APM naive or sensitive (APMN\/S) setting, the PSMAddition trial demonstrated that adding\n                    <jats:sup>177<\/jats:sup>\n                    Lu\u2010PSMA\u2010617 to standard hormonal therapy delays disease progression. In the oligorecurrent APMN\/S setting, the LUNAR trial showed that using PSMA\u2010targeted radionuclide therapy before stereotactic body radiotherapy improves progression\u2010free outcomes, suggesting a role for targeting small\u2010volume metastatic disease in patients deferring hormonal therapy. Together, these developments represent the top advances of the year and reflect a rapidly evolving and increasingly promising field of radiopharmaceutical therapy in prostate cancer.\n                  <\/jats:p>","DOI":"10.1002\/cncr.70470","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:20:30Z","timestamp":1780118430000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Top advances of the year: Radiopharmaceutical therapy for prostate cancer"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1693-3854","authenticated-orcid":false,"given":"Valentina","family":"Marulanda\u2010Corzo","sequence":"first","affiliation":[{"name":"Division of Molecular Imaging &amp; Therapeutics Department of Radiology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Coraci","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging &amp; Therapeutics Department of Radiology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging &amp; Therapeutics Department of Radiology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobechukwu Joseph","family":"Okobi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology New York Presbyterian\u2010Brooklyn Methodist Hospital  Brooklyn New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Huicochea\u2010Castellanos","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging &amp; Therapeutics Department of Radiology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Osborne","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging &amp; Therapeutics Department of Radiology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-8587","authenticated-orcid":false,"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Medical Oncology Weill Cornell Medicine  New York New York USA"},{"name":"Department of Urology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)01653\u20102"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(25)00189\u20105"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(24)00135\u20109"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(25)00009\u20109"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70474\u20107"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30860\u2010X"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.011"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.11.027"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.7_suppl.15"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(24)00440\u20106"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.101"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0147"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1483953"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201001553"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70470","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:06:17Z","timestamp":1784297177000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1002\/cncr.70470"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70470","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2026-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70470"}}